SEP 1·SEC EDGARLow
Sayad Pierre Sargis sold $146K of FENC
Sayad Pierre Sargis (Chief Medical Officer) sold 12,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $12.18 ($0.15M total) on 2026-08-31.
StockNASDAQ · US · USDHealthcare · Biotechnology
$FENC
FENNEC PHARMACEUTICALS INC.
Price · $FENCvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $FENC in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.2M 3 txs
Raykov Rosty1× · $121K
10b5-1 share of filings67%
Top stories · $FENCMore →
AUG 28·SEC EDGAR
Andrade Robert sold $884K of FENC
Andrade Robert (CHIEF FINANCIAL OFFICER) sold 75,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $11.78 ($0.88M total) on 2026-08-27 under a Rule 10b5-1 trading plan.
AUG 13·yahoo.com
Adherex Technologies Q2 Earnings Call Highlights
Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.
FENC sentiment & insider activity
Recent FENC coverage spans insider activity, earnings and market movers.
In the last 30 days, FENC insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.2M). The most active reporter was Raykov Rosty with 1 filing. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving FENC
Insider sale may signal reduced confidence or portfolio rebalancing, modest negative pressure on the stock.
Insider sale may signal CFO's view on near-term valuation.
Q2 profitability and cash runway details, alongside ongoing PEDMARK clinical and Japan trial presentation plans, can shift near-term sentiment and positioning.
Earnings beat plus accelerating PEDMARK sales and a swing to positive adjusted EBITDA likely supports near-term momentum, but higher commercial spend raises execution risk.
A beat can help reduce perceived risk for a small biotech, but the article itself flags risk and provides no trial or guidance specifics.
alphai scores every news story that mentions FENC with an AI model for sentiment and relevance, and aggregates insider trades from FENNEC PHARMACEUTICALS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $FENC
Score
Sayad Pierre Sargis sold $146K of FENC
Sayad Pierre Sargis (Chief Medical Officer) sold 12,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $12.18 ($0.15M total) on 2026-08-31.
1 min readAndrade Robert sold $884K of FENC
Andrade Robert (CHIEF FINANCIAL OFFICER) sold 75,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $11.78 ($0.88M total) on 2026-08-27 under a Rule 10b5-1 trading plan.
1 min read
Adherex Technologies Q2 Earnings Call Highlights
Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.
6 min readFennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates
Fennec Pharmaceuticals (NASDAQ:FENC) shares rose about 8% premarket after Q2 results beat estimates. Adjusted EPS was $0.05 vs $0.02 consensus. Revenue was $17.87M vs $16.39M forecast. Net product sales for PEDMARK grew 78% to $17.1M. Adjusted EBITDA turned positive at $2.8M vs a $1.2M loss. Cash was $41.2M.
4 min read
Wall Street Standouts: 9 Firms That Beat Q2 Earnings Expectations
Insider Monkey highlights nine companies that beat Q2 EPS expectations among 350+ firms reporting by Aug. 11. Reported EPS surprises include RideNow Group (RDNW) $0.16 vs $0.13, Anterix (ATEX) $0.01 vs -$0.17, Super Micro Computer (SMCI) $1.70 vs $0.96, and Fennec Pharmaceuticals (FENC) $0.05 vs $0.01. The rest of the piece shifts to AI themes and promotional content.
7 min readBiotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE
Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
7 min readFENNEC PHARMACEUTICALS INC. (FENC): Submission of Matters to a Vote of Security Holders
FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001211583 0001211583 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readRaykov Rosty sold $94K of FENC
Raykov Rosty sold 9,747 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $9.62 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min read
Fennec Pharmaceuticals advances PEDMARK as four abstracts accepted for ASCO scientific program
Fennec Pharmaceuticals announced that four scientific abstracts regarding its PEDMARK sodium thiosulfate injection have been accepted for presentation at the ASCO26 scientific program. These abstracts will focus on clinical research, patient outcomes, and ototoxicity related to chemotherapy-induced hearing loss. This selection by the American Society of Clinical Oncology highlights Fennec’s ongoing contributions to the medical community, building on its recent fiscal year 2025 earnings release and calls for greater collaboration in global health.
3 min readB.Riley initiates Fennec Pharmaceuticals stock with Buy rating, $16 target
B.Riley has initiated coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy rating and a $16 price target, citing significant undervaluation of its PEDMARK commercial potential. The firm highlights PEDMARK as the only FDA-approved therapy for cisplatin-induced hearing loss risk, with no approved competitors. Recent positive developments include record sales, an operating cash flow-positive quarter, and the company's full repayment of outstanding debt.
3 min read